News and resources search
Universal Corporation Ltd (UCL), a Strides Pharma Science Limited (Strides) enterprise, with support from MMV, has become the first African manufacturer to gain WHO prequalification for their sulfadoxine-pyrimethamine + amodiaquine product.
This report provides an overview of how MMV has been supporting African manufacturers to produce quality-assured antimalarial therapies.
Community Health Workers in clinical research at the example of a phase IIIb/ IV antimalarial drug trial conducted in five African countries
MMV at a glance is an introductory brochure sharing MMV's mission and highlighting our unique partnership model, the growth of our portfolio and the increasing impact of our access work.
A report from Zero Malaria Britain outlining how malaria threatens global health security and Britain's role in eradicating the disease.
Concerns that artemisinin combination treatments are losing their effectiveness against Plasmodium parasites have set scientists looking for alternatives.